Amneal Completes Hat Trick With Delayed $2.6bn US Pegfilgrastim Entry
Developed With Kashiv BioSciences, Fylnetra Is Sixth Biosimilar On The Market
With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.
You may also be interested in...
While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.
Amneal now expects an additional $50m in net revenue this year, revising its revenue expectations up to between $2.3bn and $2.4bn following a successful second quarter.
New Jersey-based biosimilar and 505(b)(2) specialist Kashiv Biosciences is in the race with multiple Xolair biosimilar sponsors, including frontrunner Celltrion.